Hederacoside C
产品说明书
 |
同义名 : | Kalopanaxsaponin B;Hederasaponin C;Hederoside H1;Glycoside L-H2 |
| CAS号 : | 14216-03-6 | |
| 货号 : | A351772 | |
| 分子式 : | C59H96O26 | |
| 纯度 : | 99%+ | |
| 分子量 : | 1221.378 | |
| MDL号 : | MFCD00198062 | |
| 存储条件： |
Pure form Inert atmosphere,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(85.97 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Hederacoside-C (HDC), a natural compound extracted from the leaves of Hedera helix with inflammation modulatory properties in variety of disorders. HDC pretreatment suppressed the advanced glycation end-products (AGEs) induced over-regulation of ROS level and inflammatory factors. Moreover, HDC also downregulate the degradation of ECM induced by AGEs. Mechanistically, the HDC suppressed NF-κB signaling pathway in chondrocyte[3]. Moreover, HDC may have the potential to be an effective anti-inflammatory drug for the S. aureus-induced mice mastitis and in RAW 264.7 cells[4]. HDC was administered intraperitoneally 1 h after infection until 24 h. The dose was repeated every 8 h for three successful doses. HDC significantly reduced the pulmonary edema, white blood cells, wet-dry ratio (W/D) and myeloperoxidase (MPO) activity[5]. Intravenous administration of HDC results in relatively slow clearance (1.46-2.08 mL/min/kg) and a small volume of distribution at steady state (138-222 mL/kg), while oral administration results in a low absolute oral bioavailability (F) of 0.118-0.250%[6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
0.82mL 0.16mL 0.08mL |
4.09mL 0.82mL 0.41mL |
8.19mL 1.64mL 0.82mL |
| 参考文献 |
|---|